

31 Harrison Road #11-03/04 Food Empire Building Singapore 369 649

Tel: +65 6285 0500 Fax: +65 6280 0822

(Incorporated in the Republic of Singapore under Registration Number: 199805793D)

UNAUDITED FIRST QUARTER FINANCIAL STATEMENTS AND ANNOUNCEMENT FOR THE 3 MONTHS ENDED 31 MARCH 2017 OF OCEANUS GROUP LIMITED ("OCEANUS") AND ITS SUBSIDIARIES (COLLECTIVELY KNOWN AS THE "OCEANUS GROUP")

PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3), HALF-YEAR AND FULL YEAR RESULTS

1(a) An income statement (for the Group) together with a comparative statement for the corresponding period of the immediately preceding financial year.

	3 months ended		Favourable
	31/3/2017	31/3/2016	/(Adverse)
	RMB'000	RMB'000	%
Sales of aquaculture products			
Sales of live marine products	6,915	4,906	41%
Sales of processed marine products	267	410	(35%)
Revenue	7,182	5,316	35%
Feed used	(75)	(88)	15%
Electricity, fuel and water	(448)	(243)	(84%)
Staff costs	(1,107)	(805)	(38%)
Cost of sales	(238)	(606)	61%
Total Cost of sales	(1,868)	(1,742)	(7%)
Gross Profit	5,314	3,574	49%
Other operating income	11,997	254	>100%
Staff costs	(1,016)	(1,118)	9%
Other operating expenses	(4,309)	(1,722)	(150%)
Gain arising from changes in fair value			
less cost to sell of biological assets	2,013	(2,304)	>100%
Profit/(Loss) for the year from			
discountinued operations	3,750	3	
Adjusted EBITDA (excl. Foreign			1
exchange gain or loss	17,749	(1,313)	>100%
Foreign currency gain/(loss)	45,544	15,390	NM
EBITDA	63,293	14,077	
Depreciation	(13,965)	(14,360)	3%
Finance costs	(14,524)	(13,855)	(5%)
Profit/(Loss) before income tax	34,804	(14,138)	>100%
Income tax	-	-	
Profit/(Loss) for the period	34,804	(14,138)	>100%

Profit/(Loss) for the period is arrived at after charging $\it I$ (crediting) the following items:

		3 month	s ended	Favourable / (Adverse)
		31/3/2017	31/3/2016	
		RMB'000	RMB'000	%
Con	tinuing operations			
Inter	est income	-	-	-
Inter	est expense			
(i)	Coupon rate 5%	3,848	4,381	12%
(ii)	Notional interest	9,995	8,802	(14%)
(iii)	Loan interest	-	-	0%
(iv)	Withholding tax	679	673	(1%)
(v)	Others	-	-	0%
Depr	eciation of property, plant and	13,965	14,360	3%
equip	oment			
Amo	rtisation of prepaid leases	-	123	100%
Oper	rating lease expenses	134	149	10%
Fore	ign exchange (gain)/loss	(45,544)	(15,390)	NM
Disc	ontinued operations			
Fore	ign exchange (gain)/loss	(3,912)	(2)	(>100%)

NM: Not meaningful

(b) A Statement of Comprehensive Income (for the Group) together with a comparative statement for the corresponding period of the immediately preceding financial year.

	3 month	s ended
	31/3/2017	31/3/2016
	RMB'000	RMB'000
Profit/(Loss) for the period	34,804	(14,138)
Other comprehensive income		
Exchange differences on translation of foreign operations	(53,891)	(36,446)
Total comprehensive income for the period	(19,087)	(50,584)
Attributable to:		
Equity holders of the Company	(19,087)	(50,584)

1 (c)(i) A balance sheet (for the Issuer and Group), together with a comparative statement as at the end of the immediately preceding financial year.

	Gro	oup	Compa	ny
	31/3/2017	31/12/2016	31/3/2017	31/12/2016
	RMB'000	RMB'000	RMB'000	RMB'000
ASSETS				
Current assets				
Cash and bank balances	53,999	7,181	2,425	3,170
Trade receivables	30	14	-	-
Other receivables	1,492	(2,761)	19,990	20,412
Inventories	173	72	-	-
Biological assets	10,542	8,529		
	66,236	13,035	22,415	23,582
Non-current assets				
Property, plant and equipment	96,031	141,776	-	-
Prepaid leases	7,301	7,011	-	-
Investment in subsidiaries	-	-	262,129	262,129
	103,332	148,787	262,129	262,129
Total assets	169,568	161,822	284,544	285,711
LIABILITIES AND EQUITY				
Current liabilities				
Trade payables	3,587	3,592	-	-
Other payables	112,877	107,518	89,796	81,434
Loans and borrowings	-	-	-	-
Current tax payable	23,948	23,948	-	-
Convertible loan	303,524	286,032	303,524	286,032
Derivative liabilities	175,466	170,700	175,466	170,700
	619,402	591,790	568,786	538,166
Non-current liabilities				
Convertible loan	36,179	34,582	36,179	34,582
Loans and borrowings	5,916	8,393	5,916	8,393
Derivative liabilities	1,975	1,922	1,975	1,922
Deferred tax liabilities	2,062	2,014	2,062	2,014
	46,132	46,911	46,132	46,911
Total liabilities	665,534	638,701	614,918	585,077
Capital and reserves				
Share capital	2,413,255	2,413,255	2,413,255	2,413,255
Capital reserve	(1,135,800)	(1,137,504)	11,229	11,229
Currency translation reserve	(28,178)	27,417	(10,469)	5,422
Warrant reserve	162,066	162,066	162,066	162,066
Statutory reserve	39,262	39,262	-	-
Accumulated losses	(1,946,571)	(1,981,375)	(2,906,455)	(2,891,338)
Equity attributable to equity holders of the Company	(495,966)	(476,879)	(330,374)	(299,366)
Total liabilities and equity	169,568	161,822	284,544	285,711

1(c)(ii) Aggregate amount of the Group's borrowings and debt securities.

Group

	31/3/	2017	31/12/2016	
	RMB'000	RMB'000	RMB'000	RMB'000
-	Secured	Unsecured	Secured	Unsecured
	RMB'000	RMB'000	RMB'000	RMB'000
Amount payable in one year or less, or demand	-	-	-	-
Amount repayable in one year or less	303,524	-	282,053	-
Amount repayable after one year	36,179	5,916	34,615	5,376
	339,703	5,916	316,668	5,376

Details of any collateral

Secured loans

The loans amounting to approximately RMB320 million mainly relates to a restructuring exercise which was completed on 2 September 2015. The convertible loans are secured by the creation of charges over specify Company assets. (Kindly refer to Company's circular dated 6 May 2015) for more details of these security charges.

The Company has on 3 September 2015 issued an aggregate of 2,971,069,187 Restructuring Warrants and 647,237,779 New Warrants and on 26 October 2015, issued a further 107,692,308 New Warrants.

The restructured convertible loan ("RCL") was classified as current liabilities and had expired on 31 December 2016.

Notwithstanding the expiry date of 31 December 2016, the Company had announced on 8th September 2016 that it had entered into a binding term sheet with two of three key creditors, in relation to a propose debt restructuring of the **RCL**. In the term sheet, these two key creditors have also agreed to extend the expiry date of the **RCL** to 31 December 2018. In addition, they have also agreed that interest will cease to accrue on and from 1 July 2016, upon completion of the proposed restructuring exercise. On 25 January 2017, all the 3 creditors come to an agreement to extend the expiry date of the **RCL** to 31 December 2018 and interest will cease to accrue on and from 1 July 2016 (Kindly refer to Company's announcement on 25 January 2017 for more details)

The convertible loan arising from new warrants issued to the Company's third key creditor was classified as non-current as the loan has a term of five (5) years commencing from the 1st drawdown date of 3 September 2015.

1(d) A cash flow statement (for the Group), together with a comparative statement for the corresponding period of the immediately preceding financial year.

3 months mode members Cash Flows from Operating Activities Loss before income tax 34,804 (14,138) Adjustments for: 34,804 (14,138) Gain (loss) arising from changes in fair value less cost to sell of biological assets (8,928) (2,602) Depreciation of property, plant and equipment 13,965 14,360 Amorfisation of prepaid leases 124 123 Interest income - (1) Interest expense 14,522 13,855 Net foreigin exchange difference (23,164) (15,392) Operating cash flows before working capital changes 31,323 (3,795) Trade receivables (16) 65 Other receivables (241) 478 Inventories (101) 38 Biological assets (5) (102) Other payables (4,515) 72 Cash used in/(from) operations 33,360 1,776 Interest received - - Interest received - - Interest received		Group	
RMB'000 RMB'000 Cash Flows from Operating Activities 34,804 (14,138) Loss before income tax 34,804 (14,138) Adjustments for: - - Gain (loss) arising from changes in fair value less cost to sell of biological assets (8,928) (2,602) Depreciation of property, plant and equipment 13,965 14,360 Amortisation of prepaid leases 124 123 Interest income - (1) Interest expense 14,522 13,855 Net foreign exchange difference (23,164) (15,392) Operating cash flows before working capital changes 31,323 (3,795) Trade receivables (16) 65 Other receivables (241) 478 Inventories (101) 38 Biological assets 6,915 5,020 Trade payables (5) (102) Other payables (4,515) 72 Cash used in/(from) operations 33,360 1,776 Interest received - 1<		3 months	s ended
Cash Flows from Operating Activities 34,804 (14,138) Loss before income tax 34,804 (14,138) Adjustments for: - - Gain (loss) arising from changes in fair value less cost to sell of biological assets (8,928) (2,602) Depreciation of property, plant and equipment 13,965 14,360 Amortisation of prepaid leases 124 123 Interest income - (1) Interest expense 14,522 13,855 Net foreign exchange difference (23,164) (15,392) Operating cash flows before working capital changes 31,323 (3,795) Trade receivables (16) 65 Ofter receivables (241) 478 Inventories (101) 38 Biological assets (5) (102) Trade payables (5) (102) Ofter payables (4,515) 72 Cash used in/(from) operations 33,360 1,776 Interest received - 1 Interest paid - -		31/3/2017	31/3/2016
Loss before income tax		RMB'000	RMB'000
Adjustments for:	Cash Flows from Operating Activities		
Gain (loss) arising from changes in fair value less cost to sell of biological assets (8,928) (2,602) Depreciation of property, plant and equipment 13,965 14,360 Amortisation of prepaid leases 124 123 Interest income - (1) Interest expense 14,522 13,855 Net foreign exchange difference (23,164) (15,392) Operating cash flows before working capital changes 31,323 (3,795) Trade receivables (16) 65 Other receivables (241) 478 Inventories (101) 38 Biological assets 6,915 5,020 Trade payables (5) (102) Other payables (4,515) 72 Cash used in/(from) operations 33,360 1,776 Interest received - 1 Interest paid - - Income taxes paid - - Cash flows from/(used in) operating activities 33,360 1,777 Financing activities 18,561 -	Loss before income tax	34,804	(14,138)
biological assets (8,928) (2,602) Depreciation of property, plant and equipment 13,965 14,360 Amortisation of prepaid leases 124 123 Interest income - (1) Interest expense 14,522 13,855 Net foreign exchange difference (23,164) (15,392) Operating cash flows before working capital changes 31,323 (3,795) Trade receivables (16) 65 Other receivables (241) 478 Inventories (101) 38 Biological assets 6,915 5,020 Trade payables (5) (102) Other payables (4,515) 72 Cash used in/(from) operations 33,360 1,776 Interest received - 1 Interest paid - - Income taxes paid - - Cash flows from/(used in)operating activities 33,360 1,777 Financing activities (5,103) - Proceeds from short tem loan	Adjustments for:	-	-
Depreciation of property, plant and equipment		(0.000)	(2.222)
Amortisation of prepaid leases 124 123 Interest income - (1) Interest expense 14,522 13,855 Net foreign exchange difference (23,164) (15,392) Operating cash flows before working capital changes 31,323 (3,795) Trade receivables (16) 65 Other receivables (241) 478 Inventories (101) 38 Biological assets 6,915 5,020 Trade payables (5) (102) Other payables (4,515) 72 Cash used in/(from) operations 33,360 1,776 Interest received - 1 Interest paid - - Income taxes paid - - Cash flows from/(used in)operating activities 33,360 1,777 Financing activities Proceeds from short tem loan 18,561 - Repayment of loan from investors (5,103) - Cash flows from financing activities 13,458 - Net increase (decrease) in cash and cash equivalent 46,818 1	-	, , ,	
Interest income			
Net foreign exchange difference		124	
Net foreign exchange difference (23,164) (15,392) Operating cash flows before working capital changes 31,323 (3,795) Trade receivables (16) 65 Other receivables (241) 478 Inventories (101) 38 Biological assets 6,915 5,020 Trade payables (5) (102) Other payables (4,515) 72 Cash used in/(from) operations 33,360 1,776 Interest received - 1 Interest paid - - Income taxes paid - - Cash flows from/(used in)operating activities 33,360 1,777 Financing activities 33,360 1,777 Financing activities 33,360 1,777 Cash flows from financing activities 18,561 - Cash flows from financing activities 13,458 - Net increase (decrease) in cash and cash equivalent 46,818 1,777 Cash and cash equivalent at beginning of the period 7,181 2,225 <td></td> <td>-</td> <td>` '</td>		-	` '
Operating cash flows before working capital changes 31,323 (3,795) Trade receivables (16) 65 Other receivables (241) 478 Inventories (101) 38 Biological assets 6,915 5,020 Trade payables (5) (102) Other payables (4,515) 72 Cash used in/(from) operations 33,360 1,776 Interest received - 1 Interest paid - - Income taxes paid - - Cash flows from/(used in)operating activities 33,360 1,777 Financing activities Proceeds from short tem loan 18,561 - Repayment of loan from investors (5,103) - Cash flows from financing activities 13,458 - Net increase (decrease) in cash and cash equivalent 46,818 1,777 Cash and cash equivalent at beginning of the period 7,181 2,225	·	· ·	
Trade receivables (16) 65 Other receivables (241) 478 Inventories (101) 38 Biological assets 6,915 5,020 Trade payables (5) (102) Other payables (4,515) 72 Cash used in/(from) operations 33,360 1,776 Interest received - 1 Interest paid - - Income taxes paid - - Cash flows from/(used in)operating activities 33,360 1,777 Financing activities Proceeds from short tem loan 18,561 - Repayment of loan from investors (5,103) - Cash flows from financing activities 13,458 - Net increase (decrease) in cash and cash equivalent 46,818 1,777 Cash and cash equivalent at beginning of the period 7,181 2,225			`
Other receivables (241) 478 Inventories (101) 38 Biological assets 6,915 5,020 Trade payables (5) (102) Other payables (4,515) 72 Cash used in/(from) operations 33,360 1,776 Interest received - 1 Interest paid - - Income taxes paid - - Cash flows from/(used in)operating activities 33,360 1,777 Financing activities Proceeds from short tem loan 18,561 - Repayment of loan from investors (5,103) - Cash flows from financing activities 13,458 - Net increase (decrease) in cash and cash equivalent 46,818 1,777 Cash and cash equivalent at beginning of the period 7,181 2,225	Operating cash flows before working capital changes	31,323	(3,795)
Inventories	Trade receivables	(16)	65
Biological assets 6,915 5,020 Trade payables (5) (102) Other payables (4,515) 72 Cash used in/(from) operations 33,360 1,776 Interest received - 1 Interest paid 1 Income taxes paid Cash flows from/(used in) operating activities 33,360 1,777 Financing activities Proceeds from short tem loan 18,561 - Repayment of loan from investors (5,103) - Cash flows from financing activities Net increase (decrease) in cash and cash equivalent 46,818 1,777 Cash and cash equivalent at beginning of the period 7,181 2,225	Other receivables	(241)	478
Trade payables Other payables Cash used in/(from) operations Interest received Interest paid Income taxes paid Cash flows from/(used in)operating activities Proceeds from short tem loan Repayment of loan from investors Cash flows from financing activities Net increase (decrease) in cash and cash equivalent Cash and cash equivalent at beginning of the period (4,515) 72 (4,515) 72 33,360 1,776 1 1 1,777 1 1 1,777 1 1 1,777 1 1 1,777 1 1,777 1 1,561 1 1,777 1 1 1 1 1 1 1 1 1 1 1 1 1	Inventories	(101)	38
Other payables (4,515) 72 Cash used in/(from) operations 33,360 1,776 Interest received - 1 Interest paid 1 Income taxes paid 1 Cash flows from/(used in)operating activities 33,360 1,777 Financing activities Proceeds from short tem loan 18,561 - (5,103) - (5,	Biological assets	6,915	5,020
Cash used in/(from) operations Interest received Interest paid Income taxes paid Cash flows from/(used in)operating activities Proceeds from short tem loan Repayment of loan from investors Cash flows from financing activities Net increase (decrease) in cash and cash equivalent Cash and cash equivalent at beginning of the period 1,777 33,360 1,777 1,777 1,777 1,777 1,778 1,777 1,77	Trade payables	(5)	(102)
Interest received - 1 Interest paid Income taxes paid Cash flows from/(used in)operating activities 33,360 1,777 Financing activities Proceeds from short tem loan 18,561 - (5,103) - Cash flows from financing activities 13,458 - Net increase (decrease) in cash and cash equivalent 46,818 1,777 Cash and cash equivalent at beginning of the period 7,181 2,225	Other payables	(4,515)	72
Interest paid	Cash used in/(from) operations	33,360	1,776
Income taxes paid Cash flows from/(used in)operating activities 33,360 1,777 Financing activities Proceeds from short tem loan 18,561 - (5,103) - Cash flows from financing activities 13,458 - Net increase (decrease) in cash and cash equivalent 46,818 1,777 Cash and cash equivalent at beginning of the period 7,181 2,225	Interest received	-	1
Cash flows from/(used in)operating activities Financing activities Proceeds from short tem loan Repayment of loan from investors Cash flows from financing activities Net increase (decrease) in cash and cash equivalent Cash and cash equivalent at beginning of the period 33,360 1,777 - (5,103) - (5,103) - (46,818 1,777 7,181 2,225	Interest paid	-	-
Financing activities Proceeds from short tem loan Repayment of loan from investors Cash flows from financing activities 13,458 - Net increase (decrease) in cash and cash equivalent Cash and cash equivalent at beginning of the period 7,181 2,225	Income taxes paid	-	-
Proceeds from short tem loan 18,561 - Repayment of loan from investors (5,103) - Cash flows from financing activities 13,458 - Net increase (decrease) in cash and cash equivalent 46,818 1,777 Cash and cash equivalent at beginning of the period 7,181 2,225	Cash flows from/(used in)operating activities	33,360	1,777
Proceeds from short tem loan 18,561 - Repayment of loan from investors (5,103) - Cash flows from financing activities 13,458 - Net increase (decrease) in cash and cash equivalent 46,818 1,777 Cash and cash equivalent at beginning of the period 7,181 2,225	Financing activities		
Repayment of loan from investors (5,103) - Cash flows from financing activities 13,458 - Net increase (decrease) in cash and cash equivalent 46,818 1,777 Cash and cash equivalent at beginning of the period 7,181 2,225	•	18,561	-
Cash flows from financing activities 13,458 - Net increase (decrease) in cash and cash equivalent 46,818 1,777 Cash and cash equivalent at beginning of the period 7,181 2,225	Repayment of loan from investors	(5,103)	-
Cash and cash equivalent at beginning of the period 7,181 2,225	• •	13,458	-
· • • • • • • • • • • • • • • • • • • •	Net increase (decrease) in cash and cash equivalent	46,818	1,777
Cash and cash equivalents at end of the period 53,999 4,002	Cash and cash equivalent at beginning of the period	7,181	2,225
	Cash and cash equivalents at end of the period	53,999	4,002

For the purpose of the consolidated cash flow statement, cash and cash equivalents comprise the following:

For the purpose of the consolidated cash flow statement, cash and cash equivalents comprise the	following:	
	3 months ended	
	31/3/2017	31/3/2016
	RMB'000	RMB'000
Cash and bank balances	53,999	4,002

1(d)(i) A statement (for the Issuer and Group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

	Share capital	Capital reserve	Currency translation reserve	Warrant reserve	Statutory surplus reserve funds	Accumulated losses	Total attributable to equity holders of the Company	Non controlling interest	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
The Group									
Balance as at 1 January 2016	2,413,255	(1,137,504)	62,778	162,066	39,262	(1,679,463)	(139,606)	-	(139,606)
Issue of new shares	-	-	-	-	-	-	-	-	-
Issue of new warrants	-	-	-	-	-	-	-	-	-
Loss for the period	-	-	-	-	-	(14,138)	(14,138)	•	(14,138)
Other comprehensive income									
Foreign currency translation	-	-	(36,446)	-	-	-	(36,446)	•	(36,446)
Total comprehensive income/(loss) for the									
period	-	-	(36,446)	-	-	(14,138)	(50,584)	-	(50,584)
Balance as at 31 March 2016	2,413,255	(1,137,504)	26,332	162,066	39,262	(1,693,601)	(190,190)	•	(190,190)
Balance as at 1 January 2017	2,413,255	(1,137,504)	27,417	162,066	39,262	(1,981,375)	(476,879)	-	(476,879)
Loca for the maried						24.004	24.004		24 004
Loss for the period	-	-	-	-	-	34,804	34,804	-	34,804
Other comprehensive income		4.704	(FF FOF)				(52,004)		(E2 004)
Foreign currency translation	-	- 1,704	(55,595)	-	-	-	(53,891)	•	(53,891)
Total comprehensive income/(loss) for the		4 704	(EE EOE)			24 004	(40,007)		(40.007)
period	•	1,704	(55,595)	•	-	34,804	(19,087)	•	(19,087)
Balance as at 31 March 2017	2,413,255	(1,135,800)	(28,178)	162,066	39,262	(1,946,571)	(495,966)	-	(495,966)
			,						· · /

	Share capital RMB'000	Capital reserve	Currency translation reserve RMB'000	Warrant reserve	Accumulated losses RMB'000	<u>Total</u> RMB'000
The Company	KIVID UUU	KIVI D UUU	KIVID 000	KIVID UUU	RIVIB 000	RIVID 000
Balance as at 1 January 2016	2,413,255	11,229	27,548	162,066	(2,267,655)	346,443
Issue of new shares Issue of new warrants	-	-	-	-	-	-
Loss for the period Other comprehensive income	-	-	-	-	(14,681)	(14,681)
Foreign currency translation	-	-	(19,420)	-	-	(19,420)
Total comprehensive income/(loss) for the period		-	(19,420)	-	(14,681)	(34,101)
Balance as at 31 March 2016	2,413,255	11,229	8,128	162,066	(2,282,336)	312,342
Balance as at 1 January 2017	2,413,255	11,229	5,422	162,066	(2,891,338)	(299,366)
Loss for the period Other comprehensive income	-	-	-	-	(15,117)	(15,117)
Foreign currency translation	-	-	(15,891)	-	-	(15,891)
Total comprehensive income/(loss) for the period	-		(15,891)		(15,117)	(31,008)
Balance as at 31 March 2017	2,413,255	11,229	(10,469)	162,066	(2,906,455)	(330,374)

1(d)(ii) Details of any changes in the Company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

There was no change in the Company's share capital since the end of the previous period reported on.

As of 31 March 2017, there were 3,725,999,274 outstanding warrants. If all the outstanding warrants were converted to shares, there will be 8,292,852,106 shares issued.

The Company did not have any treasury shares as at 31 March 2017.

(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

The total number of issued shares as at 31 March 2017 is 4,566,852,832 shares (31 December 2016: 4,566,852,832 shares).

(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

Not applicable.

(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.

Not applicable.

2. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.

The figures have not been reviewed or audited by the auditors.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of a matter).

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

The Group has applied the same accounting policies and methods of computation in the financial statements for the current financial period as those applied in the Group's most recently audited financial statements for the year ended 31 December 2014.

5.	If there are any changes in the accounting policies and methods of computation, including any
	required by an accounting standard, what has changed, as well as the reasons for, and the effect of,
	the change.

Not applicable.

6. Earnings per ordinary share of the Group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

	3 months ended		
	31/03/2017	31/03/2016	
a) EPS based on weighted average number of shares (RMB cents/ share)	0.76	(0.31)	
b) EPS based on fully diluted basis (RMB cents/ share)	0.76	(0.31)	
Weighted average number of shares applicable to earnings per share	4,566,852,832	4,566,852,832	
Weighted average number of shares fully diluted basis	4,566,852,832	4,566,852,832	

Basic earnings per share is calculated by dividing earnings for the period attributable to the equity holders of the Company by the weighted average number of ordinary shares issued during the financial period under review.

The dilutive earning per share is shown as the same amount as the basic earnings per share because the warrants are considered anti dilutive and ignored in the computation of diluted earnings per share.

- 7. Net asset value (for the Issuer and Group) per ordinary share based on issued share capital excluding treasury shares of the Issuer at the end of the:-
 - (a) current financial period reported on; and
 - (b) immediately preceding financial year.

	Group		Company	
	31/03/2017	31/12/2016	31/03/2017	31/12/2016
Net asset value per ordinary share based on issued share capital as at end of the period (RMB cents/share)	(10.86)	(10.44)	(7.23)	(6.56)

Net asset value for the Group and the Company as at 31 March 2017 and 31 December 2016 are computed based on 4,566,852,832 at the end of the financial period under review.

- 8. A review of the performance of the Group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:-
- (a) any significant factors that affected the turnover, costs, and earnings of the Group for the current financial period reported on, including (where applicable) seasonal or cyclical factors.

REVIEW OF RESULTS OF OPERATIONS

The Group's 1Q 2017 Adjusted EBITDA* is a profit of RMB17 million.

In RMB'000	Q1 /2017	Q1 /2016
Net Profit/(Loss)	34,804	(14,138)
Add/(deduct)		
Income tax	-	-
Depreciation	13,965	14,360
Amortisation of prepaid lease	-	
Interest ex pense	14,524	13,855
EBITDA	63,293	14,077
Foreign ex change (gain)/loss	(45,544)	(15,390)
Adjusted EBITDA	17,749	(1,313)

^{*}Adjusted EBITDA demonstrates the real operating loss excluding non-cash items e.g. depreciation, amortization, interest expense and unrealized foreign exchange gain or loss etc.

For the first quarter ended 31 March 2017 ("1Q 2017"), the Group generated revenue amounting to RMB7 million, a RMB2 million increase from RMB5 million recorded in the corresponding period of the preceding financial year ("1Q 2016").

The Group reported a 1Q 2017 net profit of RMB34 million compared to a net loss of RMB14 million for 1Q 2016.

This improvement is mainly due to:

- A RMB2 million gain arising from change in fair value less cost of sell of biological assets recognised in 1Q 2017 compared to a RMB2 million loss in 1Q 2016;
- (2) An increase in other operating income to RMB12 million from RMB0.3 million in the corresponding period last year, mainly relating to the compensation agreements for the disposal of the Group's Gulei farm to the PRC Authority;
- (3) An increase in foreign exchange gain to RMB46 million from RMB15 million in the corresponding period last year; and
- (4) An increase in other operating expenses to RMB4 million in 1Q 2017 from RMB2 million in the corresponding period last year.

After deduction of non-cash items such as depreciation, amortisation, interest expense and unrealised exchange gain/loss, the Group derived a positive EBITDA of RMB17 million for 1Q 2017, a substantial improvement compared to the EBITDA of RMB12 million for the same quarter last year.

An analysis of the results by key business segment is as follows:-

Live Marine Products

	3 months ended		Favourable	
	31/3/2017	31/3/2016	/(Adverse)	
	RMB'000	RMB'000	%	
External sales	6,915	4,906	41%	
			·	
Gain/(Loss) on fair value	2,013	(2,304)	>100%	
Other operating income	11,978	151	>100%	
Feed used	(75)	(88)	15%	
Electricity and fuel	(448)	(243)	(84%)	
Staff costs	(1,107)	(805)	(38%)	
Other operating expenses	(3,225)	(521)	(>100%)	
Net Profit/(Loss) Before Depn, Forex & Finance Cost	16,051	1,096	>100%	
			•	

Sales for live marine products in 1Q 2017 amounted to RMB7 million. This represents an increase of 41% from the RMB5 million recorded in the corresponding period last year.

Other operating income increased to RMB12 million in 1Q 2017 from RMB0.2 million in 1Q 2016 due to a compensation amount from the PRC Authority recognised in 1Q 2017 in relation to the Group's Gulei Farms.

Direct production costs (referring to feed used, electricity and fuel and staff costs) for 1Q 2017 amounted to RMB1.6 million, a 43% increase from RMB1.1 million during the same period last year due to the employment of temporary staff to support operations relating to the Group's successful spawning that contributed to the stronger 1Q 2017 topline performance in the live marine products segment.

Other operating expenses for the first quarter ended 31 March 2017 amounted to RMB3 million. This is RMB2 million higher than the RMB1 million recorded in same period last year, due to expenses incurred in relation to the Group's successful spawning.

Net profit for live marine products increased to RMB16 million in 1Q 2017 from RMB1 million, mainly due to the fair value gain on disposal of the Gulei Farms.

GROUP OPERATING ITEMS

Other operating income

Other operating income comprises mainly of discounts received from trade suppliers, scrap sales and rental income earned from the rental of farms to local farmers.

(b) any material factors that affected the cash flow, working capital, assets or liabilities of the Group during the current financial period reported on.

REVIEW OF BALANCE SHEET

Total assets of the Group increased RMB7 million to RMB169 million as at 31 March 2017 from RMB162 million as at 31 December 2016. The decrease is mainly attributed to a depreciation charge for this quarter, partially offset by an increase of cash and bank balances as a result of a repayment loan from the Group's subsidiary, Oceanus Aquaculture China, received in 1Q 2017.

Total current liabilities increased RMB27 million to RMB619 million as at 31 March 2017 from RMB592 million as at 31 December 2016. The increase was mainly due to:

- (1) A RMB5 million increase in other payables due to the accrual for professional fees, as well as effects of foreign exchange differences;
- (2) A RMB17 million increase in convertible loans due to notional interest on convertible loan for the period 3M 2017 and effects of foreign exchange differences; and
- (3) A RMB4 million increase in derivatives liabilities of due to effects of foreign exchange differences.

Non-current liabilities decreased to RMB46 million as at 31 March 2017 from RMB47 million as at 31 December 2016.

Total equity decreased to a debit balance of RMB496 million at 31 March 2017 from a debit balance of RMB477 million as at 31 December 2016. The decrease was due to 1Q 2017 profit and a reduction in currency translation reserves of RMB34 million and RMB53 million, respectively.

REVIEW OF CASH FLOW STATEMENT

The Group generated positive cash flow of RMB46 million for the three months ended 31 March 2017. This is mainly attributed by the repayment of a loan from Oceanus Aquaculture China.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not applicable.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the Group in the next reporting period and the next 12 months.

The Group continues to progress on its turnaround roadmap, recording the first operational profit (excluding one-off items) for its Live Marine Products business segment in 6 years of RMB 4 million. This was due to successful spawning despite a spate of typhoons in the PRC, bearing testament to the merits of the Group's science-and-evidence based farming approach and risk controls. The Live Marine Products segment is typically cyclical in nature due to lead time required for the spawning cycle and its financial performance thereafter is subject to sales demand. Concurrently, the Processed Marine Products segment remains profitable and continues to contribute positively.

Following the announcement on March 2, 2017 on the sale of 13 abalone farms in the PRC to the PRC Authorities, the Group has recognised RMB 42 million, or about 23% of the expected gross compensation receivable of RMB 183 million. Net proceeds from the sale will be used to repay the Group's remaining debt of \$\$20 million, following a debt restructuring exercise announced on January 24, 2017, putting the Group on track to becoming debt free. The Group is currently in the process of progressively relocating parts of its operations affected by the sale of the land farms.

The Group will continue to execute its turnaround strategies, including the diversification of its income streams via upstream and downstream extension of its value chain; working closely with leading institutions with a focus on cutting-edge aquaculture technology to further its science-and-evidence approach to farming to drive greater productivity and efficiency; as well as the recovery and strengthening of its balance sheet.

The Board and Management are reasonably optimistic that the Group will be profitable in FY2017, barring any unforeseen circumstances.

11. Dividend

(a) Current Financial Period Reported On

Any dividend declared for the current financial period reported on?

No.

(b) Corresponding Period of the Immediately Preceding Financial Year

Any dividend declared for the corresponding period of the immediately preceding financial year?

No.

(c) Date payable

Not applicable

(d) Books closure date

Not applicable.

12. If no dividend has been declared/recommended, a statement to that effect.

No dividend has been declared in respect of the current financial period.

13. If the Group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920 (1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

There is no general mandate obtained from shareholders for the interested person's transactions.

14. Use of Net Proceed from the Rights Issue

The Group had fully utilized the nets proceeds of S\$28,250,000 raised from Rights Issue as of 30 June 2014 as disclosed in the Company's Unaudited Second Quarter Financial Statements and Announcement for the 6 months ended 30 June 2014, as announced on SGX-NET on 8 August 2014.

15. Negative assurance confirmation on the interim financial results pursuant to Rule 705(5) of the listing manual.

The Board hereby confirms to the best of our knowledge, nothing has come to the attention of the Board of Directors of the Company which may render the unaudited interim financial results for the 3 months ended 31 March 2017 to be false or misleading in any material respect.

16. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7.7) under Rule 720(1) of the SGX-ST Listing Manual

The Company confirms that it has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7.7) under Rule 720(1) of the SGX-ST Listing Manual.

17. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13).

Name	Age	Relationship with any director and / or any substiantial shareholder	Current position and duties, and the year the position was held
Robert Koh Keng Guan	65	Brother of Peter Koh Heng Kang	Country Manager (China Operations) of the Group's main subsidiary, Oceanus Aquaculture China, stationed in PRC

BY ORDER OF THE BOARD

Peter Koh Heng Kang, PBM Executive Director and Chief Executive Officer

12 May 2017